|
Synonyms: clone OGD1.0.0 [2] | PF-06252616 | PF06252616
Compound class:
Antibody
Comment: Domagrozumab is a humanized monoclonal antibody targeting myostatin (MSTN), being investigated for potential therapeutic action in muscle wasting diseases.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with sequences claimed in patent US8992913 [2]. |
| References |
|
1. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. (2002)
Functional improvement of dystrophic muscle by myostatin blockade. Nature, 420 (6914): 418-21. [PMID:12459784] |
|
2. Mader MM, Apgar JR, Parris KD. (2015)
Antagonist antibodies against GDF-8 and uses therefor. Patent number: US8992913 B2. Assignee: Pfizer Inc.. Priority date: 15/06/2012. Publication date: 31/03/2015. |
